News
NICE recommends Opdivo as post-surgery treatment
Bristol Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending Opdivo (nivolumab) for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma (MIUC).